Liquidia Corporation

LT4.F·Frankfurt·Healthcare
Compare
41.78+4.63 (+12.46%)today
As of Nov 5, 8:01 AM CET · May be delayed up to 15 min · EUR

Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.

Key statistics

Previous close37.15
Open41.78
Day range—
52-week range21.8280.38
Off day high0.00%
Off 52-week high−48.02%
Volume500
Avg. volume (3M)220
Market cap3.74B
EPS (TTM)1.19
Forward P/E-70.81
P/E ratio (TTM)35.11
Dividend yield—
Beta (5Y)0.41
Shares outstanding89.51M
Short interest—
Earnings dateNov 10, 2026
Analyst target—
Profit margin30.74%

Against its peers

Compare in full ›
LT4.F LNTH LP6.F UTHR 2M7C.F 0950.HK
Market cap 3.74B 6.60B 2.33B 26.10B 2.87B 638.89M
P/E (TTM) 35.1 24.5 11.9 23.0 14.8 5.4
Forward P/E -70.8 15.6 — 18.0 — 7.8
Price/book 21.4 5.0 1.3 4.1 1.2 0.3
Dividend yield — — 7.18% — 3.42% 6.51%
1-year change +60.82% +88.38% −23.98% +34.03% −24.84% −41.58%
Today +12.46% +0.34% +0.77% +1.19% +2.61% +0.93%

The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 15 min.

Latest news

All LT4.F news ›
Trefis·

What Is Behind Liquidia’s Lead Over Its Industry?

Over the past five years, one drugmaker outperformed all 60 of its measurable pharmaceutical peers. That company is Liquidia Corporation (LQDA) (LQDA), the manufacturer of YUTREPIA, an inhalation powder form of the drug treprostinil.…

Seeking Alpha·Positive

Liquidia Is A Bargain Today

Arquitos Capital details Liquidia's legal settlement with United Therapeutics and its path forward. Read the full analysis for more details. - Liquidia will pay a net of $380.7 million in multiple installments in 2026 and 2027. - The…

From the 4Search news index, newest first.

In the news

87mentions in 30 days
87with it in the headline
Mixedsentiment

Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 87 articles, not a forecast.

Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4Search index. Terms of use. How to use Finance